Date of preparation: July 2019; GCMA code: PP-CRB-GLB-0241

Slides:



Advertisements
Similar presentations
Introduction to Competency-Based Residency Education
Advertisements

Health Problems and the Community Acute Upper Respiratory Tract Infection.
Observational study to determine the rate of occurrence of invasive mould disease and treatment outcomes in at-risk patients: a European prospective invasive.
CPT Review of Drug Administration Services AMA Presentation.
Historically, teaching on the Consultation-Liaison Psychiatry (CLP) Service was case-based. As a result, second year residents (R2s) were not systematically.
Objective Presenting Skills Review of the subject MINIMUM CONTENT: –Introduction – (History – Discovery – Early examples) –Operation principles – How does.
MEDICAL SCHEMES – A VEHICLE TO IMPROVE EMPLOYEE HEALTH Jane Ball - Medscheme.
These slides were sponsored by Janssen and developed in conjunction with the BRS CKD Strategy Group, following an advisory board that was organised by.
A S Nanivadekar Introduction to GCP. A S Nanivadekar Outline Definition and scope Definition and scope Purpose of clinical research Purpose of clinical.
UNITED HOSPITALS NHS FOUNDATION TRUST 8 th ANNUAL CANCER CONFERENCE TUESDAY 20 OCTOBER 2009 NHS IMPROVEMENT – DIRECTOR – CANCER.
Mid-Career Faculty Development: Leadership Management Training Anne L. Taylor, MD John Lindenbaum Professor of Medicine Vice Dean for Academic Affairs.
Psoriasis Network in Arabic Countries Nejib DOSS Tunisia.
Introduction Aimed at educators from wide-ranging backgrounds and with varying levels of experience, the Teaching and Assessment for Medical Educators.
#LJWG2015 HEPATITIS C IN PEOPLE WHO USE DRUGS Improving Care for Hepatitis C: A Framework Approach LONDON 2015.
ZHEJIANG UNIVERSITY iMDE: international Market- Driven Engineering Company visit 1 Taobao.
Welcome Add date Add speaker Chair Mohammed Khalil Senior Commissioning Manager SWB CCG Atrial Fibrillation Project A Structured Programme For Primary.
Introduction:. introduction Thera are 5 multigene expression based prognostic tests for breast cancer offered as reference lab test: Mammaprint,MapQuant,DX,OncotypeDX,PAM50.
1 AN INTRODUCTION TO TREAT.INFO WORKSHOPS FOR FACILITATORS.
Navigating the Proposal Process Keys to Successful Submission.
ПЕЧЕНЬ 9. Закладка печени в период эмбрионального развития.
BIO 101 Week 4 Learning Team Autoimmune Disease Describe a human autoimmune disease and address the following: Cause(s) Epidemiology Symptoms and diagnosis.
Presenter Name, Affiliation
The capacity challenge:
Reducing Death and Disability Sheila Glenn
Volume 63, Issue 1, Pages (July 2015)
Dean of the School of Nursing at Widener University
Mary McDonough RN Jeff Aalberg MD October 28, 2006 NESTFM
“An online program to enhance the quality of clinical education”.
Cough WORKING GROUP MEETING
Presenter Name, Affiliation
From: Validation of a Risk Stratification Index and Risk Quantification Index for Predicting Patient Outcomes:In-hospital Mortality, 30-day Mortality,
Making Decisions With Your Osteoarthritis Patients
A Paradigm Shift in PAH.
Handout 6: Unit assessment preparation
Challenges in the Diagnosis of MS: Physician and Nurse Perspectives
Changing the IBD Paradigm
Renal and Extrarenal Complications of ADPKD: Facilitating Better Patient Care.
الخطة الانتقالية الفردية Individuals Transition Plan (ITP)
Optimal Use of New Fentanyl Formulations for BTCP in Asia
Optimizing Patient Outcomes in IBD
Stratified Follow-Up Pathways & Living With & Beyond Cancer
IL-17 Inhibitors in the Management of Psoriatic Disease
مناهــــج البحث العلمي
SIBM: Epidemiology. sIBM: Epidemiology Disease Characteristics: Distinctive Patterns of Muscle Involvement.
Section VII: Summary New focus on treating hypertension beyond the numbers Content Points: In view of current clinical understanding of the link between.
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Examining the Latest Evidence in PAH
Quantitative PET Imaging; from Research to Clinical Use
Treating to Target in MS
The Evolving Treatment Landscape in Atopic Dermatitis
Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.
Somerset, Wiltshire, Avon & Gloucestershire Cancer Alliance
Welcome to an Introduction to Technology at Illinois State University!
Diabetes Pandemic. The Economics of Managing Patients With Diabetes and Coronary Artery Disease: A Payer Perspective.
New ELN Recommendations
Clinical Research Association TURKEY
Diagnosis of disease M2/D2
Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators
Perspective on the Multidisciplinary Management of PAH
Report Writing.
Volume 63, Issue 1, Pages (July 2015)
Title Introduction: Discussion & Conclusion: Methods & Results:
WHO methodology for the selection of priority medical devices for NCD management Medical technologies for essential cardiovascular, stroke, diabetes, and.
Component 1: Introduction to Health Care and Public Health in the U.S.
Finding the Right Sequence in Patients With EGFR-Mutated NSCLC
Teaching/training Careers
Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.
2019 ANSYS Design Analysis Competition
Care Partners Annual Meeting September 30, 2019 Davis, CA
Presentation transcript:

Date of preparation: July 2019; GCMA code: PP-CRB-GLB-0241 Tackling invasive mould disease, one patient at a time:  The value of a patient-tailored early treatment approach  Saturday 12 October, 12:30–14:00 Date of preparation: July 2019; GCMA code: PP-CRB-GLB-0241 Time (minutes) Faculty Title 12:30– 12:35 5-min introduction Professor Johan Maertens (Chair) Welcome and introduction 12:35– 12:55 20-min presentation Professor Robert Krause Evolving risk stratification and empowering diagnostics to ensure targeted treatment 12:55– 13:00 5-min discussion (facilitator) Case study part 1 13:00– 13:20 Where are we now? Epidemiology, clinical data, guidelines and challenges in the invasive mould disease landscape 13:20– 13:25 Case study part 2 13:25– 13:45 Professor Federico Pea PK/PD patient-considerations for the appropriate treatment of IMD 13:45– 13:50 Case study part 3 13:50– 14:00 10-min discussion + audience Q&A All (led by Professor Johan Maertens) Discussion, Q + A and close